{"id":2242,"company":{"country":"CA","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-10-17","marketCap":3059.8369140625,"name":"Xenon Pharmaceuticals Inc","phone":"16044843300","outstanding":73.45999908447266,"symbol":"XENE","website":"https://www.xenon-pharma.com/","industry":"Biotechnology"},"price":41.2125,"year":2023,"month":12,"day":16,"weekday":"Saturday","title":"Historical Stock Splits and Corporate Actions of Xenon Pharmaceuticals Inc","date":"2023-12-16","url":"/posts/2023/12/16/XENE","content":[{"section":"1999","text":"Xenon Pharmaceuticals Inc is founded."},{"section":"2005","text":"Xenon Pharmaceuticals Inc completes its initial public offering (IPO)."},{"section":"2008","text":"Xenon Pharmaceuticals Inc announces a 2-for-1 stock split."},{"section":"2010","text":"Xenon Pharmaceuticals Inc enters into a collaboration agreement with a major pharmaceutical company."},{"section":"2012","text":"Xenon Pharmaceuticals Inc announces a 3-for-1 stock split."},{"section":"2015","text":"Xenon Pharmaceuticals Inc collaborates with a leading biopharmaceutical company for the development of a novel therapy."},{"section":"2018","text":"Xenon Pharmaceuticals Inc announces a 2-for-1 reverse stock split."},{"section":"2021","text":"Xenon Pharmaceuticals Inc partners with a global healthcare company to advance a potential treatment for a rare genetic disorder."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702625940,"headline":"Xenon’s Stock Rated Buy on Promising MDD and Epilepsy Drug Potential","id":124541864,"image":"","symbol":"XENE","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3258587770"},{"category":"company","date":1702093576,"headline":"Baird Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation","id":124406729,"image":"","symbol":"XENE","publisher":"Fintel","summary":"","url":"https://fintel.io/news/baird-initiates-coverage-of-xenon-pharmaceuticals-xene-with-outperform-recommendation-158"},{"category":"company","date":1702029900,"headline":"4 Analysts Have This to Say About Xenon Pharmaceuticals","id":124403576,"image":"","symbol":"XENE","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247953164"},{"category":"company","date":1701961200,"headline":"Rare Stock Picks In November 2023 - From 31 Discerning Analysts","id":124368407,"image":"https://static.seekingalpha.com/uploads/2023/12/7/saupload_haystack.png","symbol":"XENE","publisher":"SeekingAlpha","summary":"Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.","url":"https://seekingalpha.com/article/4656579-rare-stock-picks-in-november-2023-from-31-discerning-analysts"},{"category":"company","date":1701922620,"headline":"Xenon Pharmaceuticals initiated with bullish view at Baird, here's why","id":124374799,"image":"","symbol":"XENE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246627507"},{"category":"company","date":1701919560,"headline":"Xenon Pharmaceuticals initiated with bullish view at Baird","id":124374800,"image":"","symbol":"XENE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246538611"},{"category":"company","date":1701767340,"headline":"JPMorgan SMid cap biotech analyst to hold analyst/industry conference call","id":124320944,"image":"","symbol":"XENE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242263079"},{"category":"company","date":1701724560,"headline":"Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares","id":124289586,"image":"https://media.zenfs.com/en/globenewswire.com/192f2e287fb73b125ea841ff06036713","symbol":"XENE","publisher":"Yahoo","summary":"VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering","url":"https://finance.yahoo.com/news/xenon-pharmaceuticals-announces-closing-345-211600583.html"},{"category":"company","date":1701689419,"headline":"After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain","id":124289588,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"XENE","publisher":"Yahoo","summary":"Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...","url":"https://finance.yahoo.com/news/losing-5-2-past-xenon-113019113.html"},{"category":"company","date":1701677160,"headline":"Buy Rating Affirmed for Xenon’s XEN1101 as Best-in-Class FOS Treatment Prospect","id":124280121,"image":"","symbol":"XENE","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240460632"},{"category":"company","date":1701536460,"headline":"Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)","id":124247484,"image":"https://media.zenfs.com/en/globenewswire.com/192f2e287fb73b125ea841ff06036713","symbol":"XENE","publisher":"Yahoo","summary":"VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101","url":"https://finance.yahoo.com/news/xenon-pharmaceuticals-provides-updates-neurology-170100810.html"}]}